These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

435 related articles for article (PubMed ID: 27314634)

  • 1. Role of anti-domain 1-β2 glycoprotein I antibodies in the diagnosis and risk stratification of antiphospholipid syndrome.
    De Craemer AS; Musial J; Devreese KM
    J Thromb Haemost; 2016 Sep; 14(9):1779-87. PubMed ID: 27314634
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical significance of anti-domain 1 β2-glycoprotein I antibodies in antiphospholipid syndrome.
    Iwaniec T; Kaczor MP; Celińska-Löwenhoff M; Polański S; Musiał J
    Thromb Res; 2017 May; 153():90-94. PubMed ID: 28363116
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thrombotic risk assessment and analytical performance of the chemiluminescent analyzer IDS-iSYS for the detection of anti-cardiolipin and anti-beta 2 glycoprotein I autoantibodies.
    Salma N; Julie L; Boutahar B; Sylvie LN; Eleonore B; Fabien LN; Elisabeth P; Sandrine JJ; Francis C; Sophie H; Yves R
    Clin Immunol; 2018 Sep; 194():92-99. PubMed ID: 30017909
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Laboratory evaluation of anti-phospholipid syndrome: a preliminary prospective study of phosphatidylserine/prothrombin antibodies in an at-risk patient cohort.
    Heikal NM; Jaskowski TD; Malmberg E; Lakos G; Branch DW; Tebo AE
    Clin Exp Immunol; 2015 May; 180(2):218-26. PubMed ID: 25522978
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The value of IgA antiphospholipid testing for diagnosis of antiphospholipid (Hughes) syndrome in systemic lupus erythematosus.
    Bertolaccini ML; Atsumi T; Escudero Contreras A; Khamashta MA; Hughes GR
    J Rheumatol; 2001 Dec; 28(12):2637-43. PubMed ID: 11764209
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Autoantibodies to beta2-glycoprotein I in systemic lupus erythematosus and primary antiphospholipid antibody syndrome: clinical correlations in comparison with other antiphospholipid antibody tests.
    Day HM; Thiagarajan P; Ahn C; Reveille JD; Tinker KF; Arnett FC
    J Rheumatol; 1998 Apr; 25(4):667-74. PubMed ID: 9558167
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of high thrombotic risk triple-positive antiphospholipid syndrome patients is dependent on anti-cardiolipin and anti-β2glycoprotein I antibody detection assays.
    Chayoua W; Kelchtermans H; Moore GW; Musiał J; Wahl D; de Laat B; Devreese KMJ
    J Thromb Haemost; 2018 Oct; 16(10):2016-2023. PubMed ID: 30079628
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical characterization of antiphospholipid syndrome by detection of IgG antibodies against β2 -glycoprotein i domain 1 and domain 4/5: ratio of anti-domain 1 to anti-domain 4/5 as a useful new biomarker for antiphospholipid syndrome.
    Andreoli L; Chighizola CB; Nalli C; Gerosa M; Borghi MO; Pregnolato F; Grossi C; Zanola A; Allegri F; Norman GL; Mahler M; Meroni PL; Tincani A
    Arthritis Rheumatol; 2015 May; 67(8):2196-204. PubMed ID: 25939498
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IgG/IgM antiphospholipid antibodies present in the classification criteria for the antiphospholipid syndrome: a critical review of their association with thrombosis.
    Kelchtermans H; Pelkmans L; de Laat B; Devreese KM
    J Thromb Haemost; 2016 Aug; 14(8):1530-48. PubMed ID: 27279342
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Do antibodies to beta2-glycoprotein 1 contribute to the better characterization of the antiphospholipid syndrome?
    Detkov ; Gil-Aguado A; Lavilla P; Cuesta MV; Fontán G; Pascual-Salcedo D
    Lupus; 1999; 8(6):430-8. PubMed ID: 10483010
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Toward harmonized interpretation of anticardiolipin and anti-β2-glycoprotein I antibody detection for diagnosis of antiphospholipid syndrome using defined level intervals and likelihood ratios: communication from the ISTH SSC Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibodies.
    Vandevelde A; Gris JC; Moore GW; Musiał J; Zuily S; Wahl D; Devreese KMJ
    J Thromb Haemost; 2024 Aug; 22(8):2345-2362. PubMed ID: 38704123
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Confirmation of initial antiphospholipid antibody positivity depends on the antiphospholipid antibody profile.
    Pengo V; Ruffatti A; Del Ross T; Tonello M; Cuffaro S; Hoxha A; Banzato A; Bison E; Denas G; Bracco A; Padayattil Jose S
    J Thromb Haemost; 2013 Aug; 11(8):1527-31. PubMed ID: 23601766
    [TBL] [Abstract][Full Text] [Related]  

  • 13. APhL antibody ELISA as an alternative to anticardiolipin test for the diagnosis of antiphospholipid syndrome.
    Suh-Lailam BB; Cromar A; Davis KW; Tebo AE
    Int J Clin Exp Pathol; 2012; 5(3):210-5. PubMed ID: 22558475
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Performance of two new, automated chemiluminescence assay panels for anticardiolipin and anti-beta2-glycoprotein I antibodies in the laboratory diagnosis of the antiphospholipid syndrome.
    Van Hoecke F; Persijn L; Decavele AS; Devreese K
    Int J Lab Hematol; 2012 Dec; 34(6):630-40. PubMed ID: 22827598
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence of antibodies to beta2-glycoprotein I in systemic lupus erythematosus and their association with antiphospholipid antibody syndrome criteria: a single center study and literature review.
    Bruce IN; Clark-Soloninka CA; Spitzer KA; Gladman DD; Urowitz MB; Laskin CA
    J Rheumatol; 2000 Dec; 27(12):2833-7. PubMed ID: 11128672
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of IgG anti-Domain I beta2 Glycoprotein I antibodies by chemiluminescence immunoassay in primary antiphospholipid syndrome.
    Meneghel L; Ruffatti A; Gavasso S; Tonello M; Mattia E; Spiezia L; Tormene D; Hoxha A; Fedrigo M; Simioni P
    Clin Chim Acta; 2015 Jun; 446():201-5. PubMed ID: 25935129
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IgG reactivity to phospholipid-bound beta(2)-glycoprotein I is the main determinant of the fraction of lupus anticoagulant activity quenched by addition of hexagonal (II) phase phospholipid in patients with the clinical suspicion of antiphospholipid-antibody syndrome.
    Safa O; Crippa L; Della Valle P; Sabbadini MG; Viganò D'Angelo S; D'Angelo A
    Haematologica; 1999 Sep; 84(9):829-38. PubMed ID: 10477458
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection of anti-domain I antibodies by chemiluminescence enables the identification of high-risk antiphospholipid syndrome patients: A multicenter multiplatform study.
    Yin D; Chayoua W; Kelchtermans H; de Groot PG; Moore GW; Gris JC; Zuily S; Musial J; de Laat B; Devreese KMJ
    J Thromb Haemost; 2020 Feb; 18(2):463-478. PubMed ID: 31749277
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of a new set of automated chemiluminescense assays for anticardiolipin and anti-beta2-glycoprotein I antibodies in the laboratory diagnosis of the antiphospholipid syndrome.
    Persijn L; Decavele AS; Schouwers S; Devreese K
    Thromb Res; 2011 Dec; 128(6):565-9. PubMed ID: 21529896
    [TBL] [Abstract][Full Text] [Related]  

  • 20. First-Line, Non-Criterial Antiphospholipid Antibody Testing for the Diagnosis of Antiphospholipid Syndrome in Clinical Practice: A Combination of Anti-β
    Nakamura H; Oku K; Amengual O; Ohmura K; Fujieda Y; Kato M; Bohgaki T; Yasuda S; Atsumi T
    Arthritis Care Res (Hoboken); 2018 Apr; 70(4):627-634. PubMed ID: 28686816
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.